Investing.com - Silk Road Medical (NASDAQ: SILK) reported fourth quarter EPS of $-0.33, $0.09 better than the analyst estimate of $-0.42. Revenue for the quarter came in at $47.27M versus the consensus estimate of $41.93M.
Guidance
Silk Road Medical sees FY 2024 revenue of $194.00M-$198.00M versus the analyst consensus of $191.40M.
Silk Road Medical's stock price closed at $17.69. It is up 81.81% in the last 3 months and down -63.01% in the last 12 months.
Silk Road Medical saw 1 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Silk Road Medical's stock price’s past reactions to earnings here.
According to InvestingPro, Silk Road Medical's Financial Health score is "good performance".
Check out Silk Road Medical's recent earnings performance, and Silk Road Medical's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar